Medical Oncology Department, ASST Sette Laghi, Ospedale di Circolo.
Department of Diagnostic and Interventional Radiology, University of Insubria, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
Anticancer Drugs. 2021 Apr 1;32(4):460-464. doi: 10.1097/CAD.0000000000000996.
Lung cancer is the most frequent cause of cancer-related death worldwide and is usually diagnosed in advanced stages. Among those, approximately 7.4% of non-small cell lung cancer (NSCLC) patients will have brain metastasis (BM) at presentation, and 25-30% will develop BM during the course of their disease. To date, patients with BMs are increasingly considered for combined treatment using systemic immune checkpoint inhibition (ICI) and cranial radiation therapy (RT); yet, there is limited data regarding the safety of this approach. Here, we report two cases of NSCLC patients treated with two different types of cranial RT and ICIs.
肺癌是全球癌症相关死亡的最常见原因，通常在晚期诊断。其中，约 7.4%的非小细胞肺癌 (NSCLC) 患者在初诊时会出现脑转移 (BM)，25-30%的患者在疾病过程中会出现 BM。迄今为止，越来越多的 BM 患者被考虑采用全身免疫检查点抑制 (ICI) 和颅放射治疗 (RT) 的联合治疗；然而，关于这种方法的安全性的数据有限。在这里，我们报告了两例接受两种不同类型颅 RT 和 ICI 治疗的 NSCLC 患者的病例。
